BGC Group says business 'performed strongly' in Q4 as stock rises
BGC Group Inc.'s stock (BGC) rose 2.7% in premarket trading on Friday after the financial technology company said its business "performed strongly" during the fourth quarter. BGC said it now expects to be "around the high-end" of its Oct. 30 guidance for revenue of $450 million to $500 million, compared to the FactSet consensus estimate of $475 million. BGC also expects to be around the high end of its guidance for pre-tax adjusted earnings of $88 million to $108 million, against the FactSet consensus estimate of $98 million. BGC Group had expected approval from the Commodity Futures Trading Commission in the fourth quarter for its FTX cash and futures trading platform, but it now sees that coming in "early 2024." The company said it will also announce its strategic partners for FTX in early 2024. "We've made significant progress with FMX on multiple fronts during the quarter," said Howard W. Lutnick, chief executive and chairman of BGC Group.
-Steve Gelsi
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
12-29-23 0840ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy as Their Stories Play Out
-
Markets Brief: Return of the Meme Stocks
-
What’s Happening In the Markets This Week
-
What Does Nvidia’s Stock Split Mean for Investors?
-
It’s Been a Terrible Time for Bonds. Here’s Why You Should Own Them
-
Which AI Stocks Are Turning Hype Into Revenue?
-
Best- and Worst-Performing Stocks of May 2024
-
3 Stocks to Buy and 3 Stocks to Sell in June
-
The Most Attractive Investment Opportunities in Oil & Gas
-
Apple: Generative AI Strategy Should Drive Sales and Upgrades
-
2 Undervalued Stocks That Just Raised Dividends
-
2 Popular Stocks That Top Managers Are Selling
-
The Best REITs to Buy
-
Nio Earnings: Revenue and Loss Largely In Line, but Vehicle Margin Missed Amid Price Competition
-
The Best Biotech Stocks to Buy
-
After Earnings, Is Marvell Stock a Buy, a Sell, or Fairly Valued?